Ad
related to: largest pharma companies by market cap
Search results
Results From The WOW.Com Content Network
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The following is a list of publicly traded companies having the greatest market capitalization, sometimes described as their "market value": [1] Market capitalization is calculated by multiplying the share price on a selected day and the number of outstanding shares on that day.
Yahoo Finance compiled a list of the biggest publicly traded companies in each state and Washington, D.C., based on market cap and the location of companies' headquarters as of 2023. Healthcare ...
List of trillion-dollar companies *Market cap data as of Dec. 13, 2024. ... The company generated about $27 billion in revenue during its fiscal 2023 and is expected to top $120 billion in sales ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Both Microsoft and Eli Lilly feature in Millennium Management's top 10 holdings, with the former accounting for 1.71% of the portfolio as of Q3 and the latter making up 0.76%.
Valeant Pharmaceuticals: Allergan, Inc: 53.3 69 Valeant raised its unsolicited offer for Allergan a second time, to $53.3 billion, increasing the cash portion of the bid in an effort to win the backing of the company, with the cash-and-stock portion of the bid valuing each Allergan share at $179.25. [26] 16 2014 Valeant Pharmaceuticals ...